


*A monthly report summarizing the Life Science transactions and trends in Washington State.*

Washington State Transactions

## Washington State Transactions by Industry



### News highlights:

- Faraday Pharmaceuticals hired Stephen Hill as the full-time CEO and has more than \$30 million in Series A commitments from its investors.
- The FDA added a new indication for Seattle Genetics' drug Adcetris for patients with Hodgkin's lymphoma at high risk of relapse after a stem-cell transplant. Adcetris is already approved for Hodgkin's lymphoma patients that have relapsed after a stem-cell transplant and patients with systemic anaplastic large cell lymphoma (sALCL).
- Adaptive Biotechnologies aims to become a drug development and discovery company and has established a new division, Adaptive Therapeutics, for this task.
- NanoString's revenue is up 20 percent compared to the same period last year; \$12.4 million compared to \$10.9 million.
- Omeros received approval for use of its first drug in Europe. The European Commission granted authorization for Omidria, which is used in cataract surgery and lens replacement procedures.

### Deal highlights:

- |   |  |
|---|--|
| • <b>Precision Image Analysis</b> \$60,348 (Equity)     | • <b>Immusoft</b> \$375,000 (Debt)                     |
| • <b>Vicis</b> \$1.5 million (Equity)                   | • <b>Sound Pharmaceuticals</b> \$300,000 (Debt)        |
| • <b>Marina Biotech</b> \$1.1 million (Equity)          | • <b>Navigating Cancer</b> \$6.6 million (Equity)      |
| • <b>Bloomington Memory Care</b> \$3.4 million (Equity) | • <b>Aqueduct Critical Care</b> \$3.7 million (Equity) |
| • <b>OtoNexus Medical Technologies</b> \$754,990 (Debt) | • <b>Kona Medical</b> \$10 million (Debt)              |

**August 2015 total:** \$17,781,740

**2015 running total:** \$2,633,803,580

This report is prepared by WBBA Commercialization Manager, Yesenia Green, PhD, [yesenia@washbio.org](mailto:yesenia@washbio.org).


\*\*The data in this report is compiled from publicly disclosed information and is not independently verified by WBBA.

August 2015

## Digital Health/Health IT in Washington

Digital Health/Health IT is a growing sector in Washington state and venture capital firms are starting to take notice.

### Digital Health/HIT Funding (Millions)



### Funding for Digital Health/ Health IT has increased from 2013 to 2015

- While private equity and debt financing has remained fairly steady between 2014 and 2015, venture capital funding has increased during this period.
- Increase in venture capital funding:
  - 41% increase from 2013 to 2014
  - 36% increase from 2014 to 2015\*

### Additional transactions:

- October 2013 – Avado acquired by WebMD – \$25M
- June 2015 – Remote Medical International finalized a contract with USAID - \$95M

\*As of September 7, 2015

## What venture capitalists are investing in Digital Health/HIT in Washington?

Top 10 digital health/HIT venture capital deals and their investors

\$36M Arivale.....	ARCH Venture Partners; Polaris Partners; Maveron
\$25M Limeade.....	Oak HC/FT; TVC Capital
\$13.3M Carena.....	Cambia Health Solutions; Martin Ventures; McKenson Ventures
\$13M Array Health.....	Healthcare Growth Partners; Noro-Moseley Partners; Vocap Investment Partners
\$8.7M Qliance Medical Management..	Cambia Health Solutions
\$8M Remotemedical International...	Columbia Pacific Management
\$6.6M Navigating Cancer.....	Merck Global Health Innovation Fund; Rustic Canyon Partners
\$6.6M Clarity Health.....	Columbia Pacific Advisors
\$4M InDemand Interpreting.....	Fifth Province Ventures; Health Enterprise Partners
\$3.5M EveryMove.....	BlueCross BlueShield Venture Partners; Sandbox Industries

## WBBA expands life science programs to Digital Health/HIT sector

### Innovate Health

An initiative to promote and support digital health innovation in Washington

Our region is dense with globally recognized healthcare providers, innovative payers, an entrepreneurial mindset and the best technology talent in the world. WBBA leverages its existing member base, infrastructure and model programs to support and help grow the health technology sector in Washington State.

For more information contact Brady Ryan at [brady@washbio.org](mailto:brady@washbio.org).

### VIP Forums

On August 19<sup>th</sup>, WBBA held the first Digital Health/Health IT focused VIP Forum, bringing investors from Cambia Health Solutions, Point B Capital, and IncWell Ventures to Seattle. These VCs met with over 30 digital health/HIT startups and held an open forum with over 100 attendees at Cambia Grove.



“Washington has all the ingredients for a world class digital health innovation cluster. We need to support startups in this sector by building community and amplifying our story.”

Russell Benaroya, CEO EveryMove

### Upcoming Events

#### 10/22/15: SAVE THE DATE: Illumina VIP Forum

8:00am Registration | 8:30–9:30 Program | 9:30am Networking  
Agora Conference Center, 1551 Eastlake Ave E, Seattle  
One-on-One Meeting Opportunity: Applications due Sept 25th  
Information available at: <http://www.washbio.org/?page=VIP>

#### 10/13/15: Lessons from Successful Digital Health and HIT Angel Investors

8:00am Registration | 8:30–9:30 Program | 10:00am Networking  
Cambia Grove, 1800 9th Ave, Seattle  
Contact: [yesenia@medtechwings.com](mailto:yesenia@medtechwings.com) for more information

This report is prepared by WBBA Commercialization Manager, Yesenia Green, PhD, [yesenia@washbio.org](mailto:yesenia@washbio.org).

\*\*The data in this report is compiled from publicly disclosed information and is not independently verified by WBBA.

## Washington-based Life Science Transactions 2015

<b>Date</b>	<b>Company</b>	<b>Type</b>	<b>Amount</b>
01/22/15	Alder Biopharmaceuticals	Second public offering	\$203,600,000
01/22/15	Adaptive Biotechnologies	Equity	\$93,750,000
01/28/15	Vesiflo	Convertible note	\$650,000
01/30/15	MalarVx, Inc	Equity	\$110,000
02/05/15	Alpine Immune Sciences	Seed	\$1,300,000
02/13/15	Stasys Medical	Series A	\$160,000
02/18/15	StratoScientific	Venture Equity	\$550,000
02/23/15	Dendreon	Acquisition	\$495,000,000
03/06/15	Cerevast Therapeutics	Series C	\$1,375,000
03/09/15	KinDex Pharmaceuticals	Series A	\$500,000
03/11/15	Cardiac Dimensions	Venture Equity	\$15,200,000
03/15/15	Medical Mirror Systems	Equity	\$250,000
03/19/15	Nortis	Venture Equity	\$408,845
03/20/15	Healthentic	Series C	\$3,750,000
03/20/15	StratoScientific	Venture Equity	\$150,000
03/25/15	Cadence Biomedical	Equity	\$959,578
04/08/15	NuvoMed	Equity	\$390,637
04/10/15	Cardeas Pharma	Series B	\$3,500,000
04/13/15	Carena	Debt	\$500,000
04/17/15	X2 Biosystems	Venture Equity	\$350,000
04/23/15	Deep Domain	Venture Equity	\$30,000
04/24/15	Mpirica Health	Series A	\$1,600,000
05/01/15	Mirabilis Medica	Debt	\$2,920,000
05/06/15	Adaptive Biotechnologies	Venture Equity	\$195,000,000
05/06/15	Theraclone Sciences	Venture Equity	\$3,080,000
05/06/15	Cyrus Biotechnology	Debt	\$850,000
05/06/15	InDemand Interpreting	Venture Equity	\$4,000,000
05/14/15	Cytodyn	Debt	\$3,281,050
05/18/15	Tissue Regeneration Systems	Debt	\$2,093,182
05/19/15	KPI Therapeutics	Equity	\$27,000
05/21/15	Ventec Life Systems	Equity	\$8,192,480
05/27/15	BioViva USA	Equity	\$250,000
06/02/15	C-SATS	Venture Equity	\$2,500,000
06/03/15	Magnolia Medical Technologies	Venture Equity	\$6,235,322
06/04/15	Carena	Series B	\$13,300,000
06/05/15	Valant Medical Solutions	Venture Equity	\$3,000,000
06/11/15	Glycostasis	Equity	\$149,998
06/16/15	Altius Institute for Biomedical Sciences	Partnership	\$95,000,000
06/16/15	Remote Medical International	Partnership	\$95,000,000
06/17/15	Stratos Genomics	Series B	\$19,999,976
06/20/15	Global Innovation Exchange	Partnership	\$45,000,000
06/22/15	Qliance Medical Management	Debt	\$520,753
06/24/15	Nativis	Venture Equity	\$725,000
06/24/15	Cadence Biomedical	Series B	\$1,200,000
06/25/15	Blaze Bioscience	Equity	\$85,400
06/28/15	Juno Therapeutics	Partnership	\$1,000,000,000
06/29/15	Nexgenia	Equity	\$1,617,582
06/30/15	Vera Whole Health, Inc	Debt	\$2,000,000
07/13/15	Arivale	Series B	\$36,000,000
07/14/15	Cytodyn	Equity	\$1,972,500
07/14/15	RF Surgical Systems	Acquisition	\$235,000,000
07/21/15	Deep Domain	Equity	\$260,507
07/31/15	Qliance Medical Management	Debt	\$2,676,730
08/07/15	Precision Image Analysis	Equity	\$60,348
08/11/15	Vicis	Venture Equity	\$1,500,000
08/12/15	Marina Biotech	Equity	\$1,100,000
08/13/15	Bloomingtondale Memory Care	Equity	\$3,373,525
08/17/15	OtoNexus Medical Technologies	Debt	\$754,990
08/18/15	Immusoft	Debt	\$375,000
08/19/15	Sound Pharmaceuticals	Debt	\$300,000
08/21/15	Navigating Cancer	Venture Equity	\$6,605,573
08/28/15	Aqueduct Critical Care	Equity	\$3,712,304
09/02/15	Kona Medical	Debt	\$10,000,300
<b>2015 Running Total as of 09/07/15</b>			<b>\$2,633,803,580</b>

This report is prepared by WBBA Commercialization Manager, Yesenia Green, PhD, [yesenia@washbio.org](mailto:yesenia@washbio.org).

*\*\*The data in this report is compiled from publicly disclosed information and is not independently verified by WBBA.*

# Washington Life Science Report



## Washington-based Life Science Transactions 2013

Date	Company	Type	Amount
01/03/13	Qliance Medical Management	Series D	\$8,650,000
01/04/13	RF Surgical Systems	Series A	\$120,000
01/30/13	Immune Design	3rd installment series B	\$10,625,000
01/31/13	FlexMinder	Series A	\$1,200,000
02/08/13	Kineta	Venture Equity	\$2,737,052
02/14/13	X2 Biosystems	NA	\$2,000,000
02/15/13	Healionics	NA	\$50,000
02/20/13	Miribilis Medica	NA	\$120,000
02/20/13	Ventec Life Systems	Venture Equity	\$6,800,000
02/22/13	Blaze Bioscience	Series A	\$8,500,000
02/22/13	Endogastric Solutions	Debt	\$10,000,000
02/27/13	Resolve Therapeutics	Partnership	\$8,000,000
03/01/13	Cadence Biomedical	Venture Equity	\$213,000
04/01/13	EveryMove	Series A	\$3,500,000
04/03/13	Avado	Seed equity	\$1,000,000
03/05/13	PreSage Biosciences	Partnership	\$13,000,000
03/12/13	Appature	Acquisition	NA
03/12/13	Spiral Genetics	Venture Equity	\$3,200,000
03/25/13	Theraclone Sciences	Series B	\$14,000,000
04/02/13	Cardiac Dimensions	debt	\$2,730,000
04/02/13	Cerevast Therapeutics	Venture Equity	\$1,500,000
04/11/13	Atossa Genetics	Venture Equity	\$100,000
04/17/13	Beat BioTherapeutics	Debt	\$2,500,000
04/18/13	NuvoMed	Equity	\$485,000
04/19/13	Miribilis Medica	Debt	\$100,000
05/13/13	NanoString Technologies	Venture Equity	\$150,000
05/23/13	Cardeas Pharma	Series B	\$34,000,000
05/23/13	Valant Medical Solutions	Venture Equity	\$784,000
05/24/13	Remote Medical International	Venture Equity	\$8,000,000
05/24/13	Ekos	Acquisition	\$180,000,000
05/28/13	VentriPoint	Debt	\$750,000
05/30/13	Cadence Biomedical	Grant (US DoD)	\$1,000,000
05/30/13	Oncothyreon	Stock sale	\$10,000,000
06/03/13	AVM Biotechnology	Venture Equity	\$708,000
06/05/13	Mobisante	Venture Equity	\$4,200,000
06/06/13	Cheetah Medical	Venture Equity	\$14,500,000
06/12/13	Immune Design	Partnership	\$10,000,000
06/14/13	Miribilis Medica	Venture Equity	\$7,000,000
06/18/13	Exo Labs	NA	\$836,000
06/20/13	X2 Biosystems	Venture Equity	\$1,200,000
06/25/13	Seattle Genetics - Bayer deal	Partnership	\$20,000,000
06/26/13	NanoString Technologies	IPO	\$54,000,000
06/27/13	Lifecom	Series A	\$1,100,000
06/28/13	Blaze Biosciences	Series B	\$8,100,000
07/12/13	PhaseRx	Debt	\$500,000
07/12/13	X2 Biosystems	Debt	\$720,000
08/15/13	Project Violet	NewCo	\$20,000,000
08/16/13	Tissue Regeneration Systems	Venture Equity	\$4,600,000
08/19/13	Allozyne	Debt	\$2,500,000
09/03/13	Oncofactor	Venture Equity	\$1,000,000
09/03/13	Alpine Bioventures formed	Investor	\$5,000,000
09/09/13	Stratos Genomics	Venture Equity	\$2,000,000
09/16/13	Adaptive Biotechnologies	Grant (NIH)	\$2,530,000
09/20/13	Integrated Diagnostics	NewCo	\$1,500,000
10/03/13	PhaseRx	Debt	\$1,400,000
10/10/13	Kineta	Venture Equity	\$760,000
10/15/13	Qliance Medical Management	Venture Equity	\$5,500,000
10/16/13	Sound Pharmaceuticals	Venture Equity	\$6,000,000
10/16/13	Cardiac Dimensions	debt	\$555,000
10/21/13	Kona Medical	Venture Equity	\$10,000,000
10/29/13	Avado	Acquisition	\$25,000,000
10/30/13	Immune Design	Venture Equity	\$49,000,000
11/04/13	Kineta	NIH Grant	\$6,800,000
11/15/13	Cell Therapeutics	Partnership	\$60,000,000
11/26/13	Cerevast Therapeutics	Debt	\$1,780,000
11/27/13	Impel NeuroPharma	Venture Equity	\$2,640,000
12/05/13	Clarity Health	Series B	\$6,600,000
12/03/13	Blaze Bioscience	Series B*	\$900,000
12/05/13	Juno Therapeutics	Series A	\$120,000,000
12/10/14	Integrated Diagnostics	Seed equity	\$300,000
12/27/13	X2 Biosystems	Venture Equity	\$5,000,000
<b>2013 Total</b>			<b>\$800,043,052</b>

## Washington-based Life Science Transactions 2014

Date	Company	Type	Amount
01/07/14	Cardiac Dimensions	Debt	\$367,000
01/08/14	Seattle Genetics	Partnership	\$25,000,000
01/13/14	Juno Therapeutics	Series A extension	\$25,000,000
01/13/14	ActX	Seed equity	\$1,900,000
01/14/14	NuvoMed	Undisclosed	\$535,000
01/21/14	Seattle Genetics	Partnership	\$9,000,000
02/04/14	Acucela	IPO (Japan)	\$162,000,000
02/12/14	Cardiac Dimensions	debt	\$456,000
02/12/14	Nativis	Venture Equity	\$9,160,000
03/05/14	Immunexpress	Venture Equity	\$6,000,000
03/14/14	Kineta	Venture Equity	undisclosed
03/14/14	Nortis	Undisclosed	\$1,200,000
03/17/14	CadenceMD	Debt	\$55,000
03/20/14	Cardiac Dimensions	Debt	\$380,000
03/25/14	Clarity Health	Venture Equity	\$836,000
03/25/14	BioLife Solutions	IPO	\$15,400,000
03/25/14	FlexMinder	Series A	\$1,200,000
03/26/14	KinDex Pharmaceuticals	Series A	\$5,000,000
04/07/14	Adaptive Biotechnologies	Series C&D	\$105,000,000
04/09/14	Oricula Therapeutics	Seed equity	\$122,000
04/10/14	Tissue Regeneration Systems	Venture Equity	\$1,500,000
04/14/14	JeNu Biosciences	Debt	\$1,480,000
04/14/14	Etubics	Seed equity	\$4,400,000
04/16/14	Cardiac Dimensions	Venture Equity	\$20,000,000
04/18/14	X2 Biosystems	Debt	\$2,510,000
04/24/14	Juno Therapeutics	Series A extension	\$31,000,000
04/29/14	Integrated Diagnostics	Series B and Debt	\$47,250,000
05/08/14	Alder Biopharmaceuticals	IPO	\$80,000,000
05/13/14	Stratos Genomics	Series B	\$10,000,000
05/14/14	PharmaIN	Venture Equity	\$1,500,000
05/15/14	AVM Biotechnology	Series B	\$1,500,000
05/16/14	Kineta	Equity	\$1,627,498
06/06/14	NanoString Technologies	Partnership	\$5,750,000
06/15/14	Cardiac Insight	Partnership	\$7,000,000
07/01/14	Pregenen	Acquired	\$20,000,000
07/11/14	Nortis	Venture Equity	\$1,000,000
07/15/14	Valant Medical Solutions	Venture Equity	\$11,000,000
07/18/14	ActX	Venture Equity	\$750,000
07/21/14	Nativis	Undisclosed	\$2,319,000
07/25/14	Immune Design	IPO	\$60,000,000
07/29/14	Accelerator Corporation	Venture Equity	\$51,100,000
07/29/14	Amgen	Closing WA Offices	
07/30/14	Theraclone Sciences	Partnership	undisclosed
07/30/14	Array Health	Debt	10/14/73
07/30/14	Jintronix	Debt	\$772,500
08/04/14	Juno Therapeutics	Series B	\$134,000,000
08/07/14	Immune Design	License	\$168,000,000
08/11/14	Alpine BioSciences	Acquisition	\$27,000,000
08/15/14	Carena	Debt	\$1,995,000
08/21/14	Immunosoft	Venture Equity	\$2,300,000
09/02/14	Clarity Health	Venture Equity	\$1,059,352
09/03/14	NovoNordisk	Closing Inflammatory Research Center	
09/10/14	Seattle Genetics	Licensing	\$11,000,000
09/15/14	Tissue Regeneration Systems	Debt	\$500,000
09/23/14	VentirX Pharmaceuticals	Venture Equity	\$19,300,000
09/26/14	Array Health	Series A	\$13,000,000
10/01/14	NovoNordisk	Opening Obesity R&D	
10/07/14	Cardiac Dimensions	Venture Equity	\$8,500,000
10/08/14	Blaze BioScience	NCI SBIR Phase II Funding	\$1,500,000
10/09/14	Mirador Biomedical	Acquired	undisclosed
10/27/14	Limeade	Series C	\$25,000,000
11/19/14	IDRI	Contract	\$3,600,000
11/21/14	Aortica	Series A	\$7,000,000
12/09/14	Allen Institute for Cell Science	Paul Allen Donation	\$100,000,000
12/19/14	Juno Therapeutics	IPO	\$264,600,000
12/30/14	Oncogenex	Venture Equity	\$27,000,000
12/30/14	Cerevast Therapeutics	Venture Equity	\$10,000,000
<b>2014 Total</b>			<b>\$1,556,524,350</b>

This report is prepared by WBBA Commercialization Manager, Yesenia Green, PhD, [yesenia@washbio.org](mailto:yesenia@washbio.org).

*\*\*The data in this report is compiled from publicly disclosed information and is not independently verified by WBBA.*